| Literature DB >> 15992124 |
Abstract
In this review, the pharmacokinetics, safety and tolerability, and clinical efficacy of ropinirole (Requip), a non-ergoline dopamine agonist approved for use in the treatment of Parkinson's disease (PD) are examined. A summary of preclinical and clinical studies is presented. Ropinirole is safe and efficacious as monotherapy in the treatment of early PD and as an adjunct to levodopa in more advanced cases.Entities:
Year: 1999 PMID： 15992124 DOI： 10.1517/13543784.8.5.697
Source DB: PubMed Journal: Expert Opin Investig Drugs ISSN： 1354-3784 Impact factor: 6.206